How to Buy Monte Rosa Therapeutics Stock
Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Monte Rosa Therapeutics stock last closed at $4.91, down 0.2% from the previous day, and has increased 22.44% in one year. It has overperformed other stocks in the Biotechnology industry by 0.99 percentage points. Monte Rosa Therapeutics stock is currently +52.96% from its 52-week low of $3.21, and -60.4% from its 52-week high of $12.40.
As of Jun 13, 2025, there are 61.51M GLUE shares outstanding. The market cap of GLUE is $302.01M. In the past 24 hours, 381,000 GLUE shares were traded.
How to Buy Monte Rosa Therapeutics Stock
Wondering how to invest in Monte Rosa Therapeutics stock? Here's how.
- Figure out where to buy Monte Rosa Therapeutics stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you determine where to buy Monte Rosa Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Select your payment method and add your details.
- Research Monte Rosa Therapeutics stock: The Monte Rosa Therapeutics ticker symbol is GLUE. Is Monte Rosa Therapeutics stock a good investment? Should you buy shares of GLUE? How do GLUE's underlying business fundamentals look? Do top analysts think Monte Rosa Therapeutics is a good buy? Why has GLUE's stock price moved recently? (Hint: Our stock market research website can help you decide if GLUE is a good stock to buy).
- Execute your GLUE purchase: Decide if you will purchase GLUE shares at the current market price or use a limit order to purchase GLUE stock at a specific price.
- Keep tabs on your GLUE investment: Create a watchlist to the latest updates on your investment in Monte Rosa Therapeutics stock.
Step 1: Figure out where to buy Monte Rosa Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy GLUE shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal information so you can buy GLUE stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've opened your account on the best stock app to use, you can securely and quickly fund your account:
Check out the walkthrough below if you need help depositing money into your brokerage account.
Step 4: Research Monte Rosa Therapeutics stock
Once you have identified the best place to buy Monte Rosa Therapeutics stock, it's critical to analyze their stock before you buy, so you actually comprehend the risk as well as the upside.
Monte Rosa Therapeutics quick stats
Monte Rosa Therapeutics Overview
WallStreetZen was built to help part-time investors do better fundamental analysis quickly.
You can view all of the due diligence checks on GLUE's stock page.
Is GLUE stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge GLUE's true value.
Using relative valuations ratios:
- GLUE may be undervalued based on its P/E ratio of 61.38x, relative to Biotechnology industry P/E ratio of -108.97x
- GLUE may be undervalued based on its P/B ratio of 1.1x, relative to Biotechnology industry P/B ratio of 4.66x
You can do more valuation research on GLUE's stock here.
GLUE Financial Summary
Signs that GLUE is financially healthy:
- GLUE earnings of $9.46M is not enough to cover its interest payments.
- GLUE's operating cash flow of $34.67M allows it to safely service it's debt of $41.86M.
- There are more short-term assets than long-term liabilities on the GLUE balance sheet.
- There are more short-term assets than short-term liabilities on the GLUE balance sheet.
- GLUE profit margin has gone up from -12,714.5% to 3.9% in the past year.
Signs that GLUE is not financially healthy:
- GLUE has a relatively high debt to equity ratio of 0.43.
Do Wall Street analysts think it's a good time to buy GLUE stock
Out of 2 Wall Street analysts who give forecasts on GLUE, the consensus analyst rating on Monte Rosa Therapeutics is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Monte Rosa Therapeutics stock forecast page.
GLUE Trading Indicators
Is GLUE Making Money?
Last year, GLUE revenue was $159.49M. In the past 1 years, GLUE's revenue has gone up by 14,889.38% per year. This was faster than the Biotechnology industry average of 43.24%.
Dive into GLUE's earnings and revenue performance here.
Are GLUE insiders buying or selling the stock?
In the past 12 months, insiders at GLUE have sold more shares than they have bought.
Edmund Dunn, Principal Accounting Officer of GLUE, was the latest GLUE insider to sell. They sold $9,173.84 worth of GLUE stock on Jun 3, 2025.
Research more about who owns GLUE stock here.
Does GLUE stock generate passive income?
No, Monte Rosa Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about GLUE?
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your GLUE purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific dollar amount limit, place a limit order.
Hit the Open button and eToro will execute your order.
If you need more help with investing in stocks on eToro, watch the helpful video below:
Step 6: Keep tabs on your GLUE investment
Now that you own some GLUE stock, you'll want to stay up-to-date on your shares.
Create a watchlist to get notified of the latest news about your GLUE stock.
GLUE Feed
How to Buy Stock in Monte Rosa Therapeutics
To reiterate, here are the 6 steps for buying Monte Rosa Therapeutics stock:
- Figure out where to buy Monte Rosa Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Research Monte Rosa Therapeutics stock
- Execute your GLUE purchase
- Keep tabs on your GLUE investment
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to track your new investment in Monte Rosa Therapeutics, create a watchlist today.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.